These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

123 related items for PubMed ID: 1384952

  • 1. Acute arterial thrombosis after escalated-dose methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy with recombinant granulocyte colony-stimulating factor. A possible new recombinant granulocyte colony-stimulating factor toxicity.
    Conti JA, Scher HI.
    Cancer; 1992 Dec 01; 70(11):2699-702. PubMed ID: 1384952
    [Abstract] [Full Text] [Related]

  • 2. Escalated dosages of methotrexate, vinblastine, doxorubicin, and cisplatin plus recombinant human granulocyte colony-stimulating factor in advanced urothelial carcinoma: an Eastern Cooperative Oncology Group trial.
    Loehrer PJ, Elson P, Dreicer R, Hahn R, Nichols CR, Williams R, Einhorn LH.
    J Clin Oncol; 1994 Mar 01; 12(3):483-8. PubMed ID: 7509853
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Impact of recombinant human granulocyte colony stimulating factor on dose intensity and toxicity of three cycles of methotrexate, vinblastine, doxorubicin and cisplatin in patients with previously untreated urothelial bladder carcinoma.
    Viens P, Gravis G, Bladou F, Lechevallier E, Baume D, Camerlo J, Cowen D, Coulange C, Serment G, Resbeut M, Maraninchi D.
    Eur Cytokine Netw; 1996 Sep 01; 7(3):395-9. PubMed ID: 8954183
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. A phase II study of methotrexate, vinblastine, doxorubicin and cisplatin plus recombinant human granulocyte-macrophage colony stimulating factors in patients with advanced transitional cell carcinoma.
    Moore MJ, Iscoe N, Tannock IF.
    J Urol; 1993 Oct 01; 150(4):1131-4. PubMed ID: 8371371
    [Abstract] [Full Text] [Related]

  • 7. Schedule-intensified M-VAC chemotherapy for advanced urothelial cancer with recombinant human granulocyte colony stimulating factor (rhG-CSF).
    Noguchi S, Kubota Y, Shuin T, Hosaka M, Miura T, Kondoh I.
    Int J Urol; 1994 Jun 01; 1(2):140-2. PubMed ID: 7543010
    [Abstract] [Full Text] [Related]

  • 8. M-VEC (methotrexate, vinblastine, epirubicin, and cisplatin) with granulocyte colony-stimulating factor for the treatment of urothelial cancer: an effective and safe chemotherapy regimen.
    Igawa M, Kadena H, Ueda M, Usui T.
    Cancer Chemother Pharmacol; 1994 Jun 01; 35 Suppl():S1-4. PubMed ID: 7527732
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Escalated therapy for refractory urothelial tumors: methotrexate-vinblastine-doxorubicin-cisplatin plus unglycosylated recombinant human granulocyte-macrophage colony-stimulating factor.
    Logothetis CJ, Dexeus FH, Sella A, Amato RJ, Kilbourn RG, Finn L, Gutterman JU.
    J Natl Cancer Inst; 1990 Apr 18; 82(8):667-72. PubMed ID: 2181151
    [Abstract] [Full Text] [Related]

  • 12. Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium.
    Gabrilove JL, Jakubowski A, Scher H, Sternberg C, Wong G, Grous J, Yagoda A, Fain K, Moore MA, Clarkson B, Oettgen HF, Alton K, Welte K, Souza L.
    N Engl J Med; 1988 Jun 02; 318(22):1414-22. PubMed ID: 2452983
    [Abstract] [Full Text] [Related]

  • 13. Shorter interval between cycles of cyclophosphamide, doxorubicin, cisplatin using recombinant human granulocyte colony-stimulating factor for urothelial cancer--phase I/II study.
    Yoshida O, Kakehi Y, Arai Y, Tomoyoshi T, Okada Y, Matsuda T, Mikami O, Fukuyama T, Hida S, Okabe T.
    Int J Urol; 1995 Nov 02; 2(5):316-21. PubMed ID: 8749950
    [Abstract] [Full Text] [Related]

  • 14. Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924.
    Sternberg CN, de Mulder PH, Schornagel JH, Théodore C, Fossa SD, van Oosterom AT, Witjes F, Spina M, van Groeningen CJ, de Balincourt C, Collette L, European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group.
    J Clin Oncol; 2001 May 15; 19(10):2638-46. PubMed ID: 11352955
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Efficacy of dose-intensified MEC (methotrexate, epirubicin and cisplatin) chemotherapy for advanced urothelial carcinoma: a prospective randomized trial comparing MEC and M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin). Japanese Urothelial Cancer Research Group.
    Kuroda M, Kotake T, Akaza H, Hinotsu S, Kakizoe T.
    Jpn J Clin Oncol; 1998 Aug 15; 28(8):497-501. PubMed ID: 9769784
    [Abstract] [Full Text] [Related]

  • 17. Escalated MVAC with or without recombinant human granulocyte-macrophage colony-stimulating factor for the initial treatment of advanced malignant urothelial tumors: results of a randomized trial.
    Logothetis CJ, Finn LD, Smith T, Kilbourn RG, Ellerhorst JA, Zukiwski AA, Sella A, Tu SM, Amato RJ.
    J Clin Oncol; 1995 Sep 15; 13(9):2272-7. PubMed ID: 7666085
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. [M-VAC chemotherapy for advanced urothelial cancer--side effects and their management].
    Noguchi S, Kubota Y, Shuin T, Masuda M, Misaki H, Yao M, Kondoh K, Sakuramoto T, Hosaka M.
    Hinyokika Kiyo; 1994 Aug 15; 40(8):677-82. PubMed ID: 7942364
    [Abstract] [Full Text] [Related]

  • 20. Phase II randomized trial of gallium nitrate plus fluorouracil versus methotrexate, vinblastine, doxorubicin, and cisplatin in patients with advanced transitional-cell carcinoma.
    McCaffrey JA, Hilton S, Mazumdar M, Sadan S, Heineman M, Hirsch J, Kelly WK, Scher HI, Bajorin DF.
    J Clin Oncol; 1997 Jun 15; 15(6):2449-55. PubMed ID: 9196161
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.